APA (7th ed.) Citation

Pozorski, V., Park, Y., Mohamoud, Y., Tesfamichael, D., Emamekhoo, H., Birbrair, A., . . . Ma, V. T. (2023). Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy. Pigment Cell & Melanoma Research, 36(6), 501. https://doi.org/10.1111/pcmr.13109

Chicago Style (17th ed.) Citation

Pozorski, Vincent, Yeonhee Park, Yusuf Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair, Mark R. Albertini, and Vincent T. Ma. "Neutrophil‐to‐eosinophil Ratio as a Biomarker for Clinical Outcomes in Advanced Stage Melanoma Patients Treated with Anti‐PD‐1 Therapy." Pigment Cell & Melanoma Research 36, no. 6 (2023): 501. https://doi.org/10.1111/pcmr.13109.

MLA (9th ed.) Citation

Pozorski, Vincent, et al. "Neutrophil‐to‐eosinophil Ratio as a Biomarker for Clinical Outcomes in Advanced Stage Melanoma Patients Treated with Anti‐PD‐1 Therapy." Pigment Cell & Melanoma Research, vol. 36, no. 6, 2023, p. 501, https://doi.org/10.1111/pcmr.13109.